Orphazyme A/S, a biopharmaceutical company, develops therapies for the treatment of neurodegenerative orphan diseases.
Adequate balance sheet with moderate growth potential.
Share Price & News
How has Orphazyme's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: ORPHA has not had significant price volatility in the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: ORPHA exceeded the Danish Biotechs industry which returned 36.1% over the past year.
Return vs Market: ORPHA exceeded the Danish Market which returned 22.3% over the past year.
Price Volatility Vs. Market
How volatile is Orphazyme's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 month ago | Simply Wall StWhat Kind Of Shareholders Own Orphazyme A/S (CPH:ORPHA)?
4 months ago | Simply Wall StHere's Why We're Watching Orphazyme's (CPH:ORPHA) Cash Burn Situation
6 months ago | Simply Wall StDo Institutions Own Orphazyme A/S (CPH:ORPHA) Shares?
Is Orphazyme undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate ORPHA's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate ORPHA's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: ORPHA is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.
PE vs Market: ORPHA is unprofitable, so we can't compare its PE Ratio to the Danish market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate ORPHA's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: ORPHA is overvalued based on its PB Ratio (40.3x) compared to the XE Biotechs industry average (4.4x).
How is Orphazyme forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ORPHA is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (0.3%).
Earnings vs Market: ORPHA is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: ORPHA's is expected to become profitable in the next 3 years.
Revenue vs Market: Insufficient data to determine if ORPHA's revenue is forecast to grow faster than the Danish market.
High Growth Revenue: Insufficient data to determine if ORPHA's revenue is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: ORPHA is forecast to be unprofitable in 3 years.
How has Orphazyme performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ORPHA is currently unprofitable.
Growing Profit Margin: ORPHA is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: ORPHA is unprofitable, and losses have increased over the past 5 years at a rate of -43.7% per year.
Accelerating Growth: Unable to compare ORPHA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ORPHA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (17.1%).
Return on Equity
High ROE: ORPHA has a negative Return on Equity (-637.16%), as it is currently unprofitable.
How is Orphazyme's financial position?
Financial Position Analysis
Short Term Liabilities: ORPHA's short term assets (DKK148.2M) exceed its short term liabilities (DKK66.0M).
Long Term Liabilities: ORPHA's short term assets (DKK148.2M) exceed its long term liabilities (DKK61.8M).
Debt to Equity History and Analysis
Debt Level: ORPHA's debt to equity ratio (121.6%) is considered high.
Reducing Debt: Insufficient data to determine if ORPHA's debt to equity ratio has reduced over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ORPHA has sufficient cash runway for 4 months based on last reported free cash flow, but has since raised additional capital.
Forecast Cash Runway: ORPHA is forecast to have sufficient cash runway for 3 months based on free cash flow estimates, but has since raised additional capital.
What is Orphazyme's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate ORPHA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate ORPHA's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if ORPHA's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ORPHA's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of ORPHA's dividend in 3 years as they are not forecast to pay a notable one for the Danish market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Kim Stratton (57yo)
Ms. Kim Stratton has been Chief Executive Officer of Orphazyme A/S since October 1, 2019. Ms. Stratton has been a Director at Vifor Pharma AG since May 08, 2019. Ms. Stratton was the Head of International ...
|Chief Executive Officer||0.67yr||no data||no data|
|Co-Founder & Chief Scientific Officer||11.42yrs||no data||no data|
|Chief Financial Officer||4.08yrs||no data||0.49% DKK14.2m|
|Chief Medical Officer||3.58yrs||no data||no data|
Experienced Management: ORPHA's management team is considered experienced (3.8 years average tenure).
|Independent Director||3.42yrs||no data||no data|
|Independent Director||5.42yrs||no data||no data|
|Independent Chairman||5.83yrs||no data||0.36% DKK10.4m|
|Independent Deputy Chairman||3.42yrs||no data||0.37% DKK10.8m|
|Independent Director||10.42yrs||no data||no data|
|Independent Director||2.58yrs||no data||0.051% DKK1.5m|
|Independent Director||3.42yrs||no data||0.030% DKK854.0k|
|Independent Director||10.42yrs||no data||0.17% DKK4.9m|
Experienced Board: ORPHA's board of directors are considered experienced (4.4 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 35.3%.
Orphazyme A/S's company bio, employee growth, exchange listings and data sources
- Name: Orphazyme A/S
- Ticker: ORPHA
- Exchange: CPSE
- Founded: 2009
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: ø2.894b
- Shares outstanding: 27.04m
- Website: https://www.orphazyme.com
Number of Employees
- Orphazyme A/S
- Ole MaalOees Vej 3
- Capital Region of Denmark
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|ORPHA||CPSE (OMX Nordic Exchange Copenhagen)||Yes||Common Shares||DK||DKK||Nov 2017|
|1TB||DB (Deutsche Boerse AG)||Yes||Common Shares||DE||EUR||Nov 2017|
|0CUM||LSE (London Stock Exchange)||Yes||Common Shares||GB||DKK||Nov 2017|
|OZYM.F||OTCPK (Pink Sheets LLC)||Yes||Common Shares||US||USD||Nov 2017|
Orphazyme A/S, a biopharmaceutical company, develops therapies for the treatment of neurodegenerative orphan diseases. The company focuses on developing therapies for diseases caused by misfolding of proteins, including lysosomal storage diseases. Its lead candidate is the Arimoclomol, which is in clinical development for four orphan diseases, including Niemann-Pick disease type C, Gaucher disease, sporadic inclusion body myositis, and amyotrophic lateral sclerosis. The company was founded in 2009 and is headquartered in Copenhagen, Denmark.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/06/03 00:56|
|End of Day Share Price||2020/06/02 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.